Inhibition of SARS-CoV-2 infection by vaccine-induced antibodies and small-interfering RNAs

to connected objects

Alternative title: Hemmung der SARS-CoV-2-Infektion durch Impfstoff-induzierte Antikörper und small-interfering RNAs

Location: Deutsche Nationalbibliothek Frankfurt am Main

Extent: Online-Ressource

Language: Englisch

Notes: München, Technische Universität München, Dissertation, 2023

Keyword: COVID-19
SARS-CoV-2
Pandemie
Impfstoff
Pathogenese
Virusinfektion

Event: Veröffentlichung

(where): München

(who): Universitätsbibliothek der TU München

(when): 2023

Creator: Cheng, Cho-Chin

Contributor: Protzer-Knolle, Ulrike
Ehmer, Ursula
Rad, Radu Roland
Keppler, Oliver T.

URN: urn:nbn:de:bvb:91-diss-20231023-1716484-1-9

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 25.03.2025, 1:41 PM CET

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Cheng, Cho-Chin
Protzer-Knolle, Ulrike
Ehmer, Ursula
Rad, Radu Roland
Keppler, Oliver T.
Universitätsbibliothek der TU München

Time of origin

2023

Other Objects (12)

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2

Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2

Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2

Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Inhibition of SARS-CoV-2 infection by vaccine-induced antibodies and small-interfering RNAs

Object Details

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Time of origin

Other Objects (12)

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2

Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2

Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies

Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2

The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency

Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies

Quantitation of SARS-CoV-2 neutralizing antibodies using virus-like particles

Generation and Characterization of Monoclonal Antibodies directed against SARS-CoV-2

Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Management of suspected and confirmed COVID‐19 (SARS‐CoV‐2) vaccine hypersensitivity

Vaccine response against SARS-CoV-2 under immunomodulatory systemic therapies in dermatology

COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection

Related objects

Reset password